Moore Capital Management’s Moderna MRNA Stock Holding History

Moore Capital Management’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-50,000	Closed	-$5.16M	–	500
2023 Q3	$5.16M	Buy	+50,000	New	+$5.58M	0.1%	158

Other funds holding MRNA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Moore Capital Management's MRNA Position: Q4 2021 in Review

Moore Capital Management sold out of Moderna (MRNA) in Q4 2021, closing a stake of 190,000 shares — an estimated $73.1M sold.

Moore Capital Management first reported a position in MRNA in Q3 2021 and held it in 1 quarter. The position peaked at $73.1M in Q3 2021. 1,109 funds tracked by Wall St. Rank hold MRNA as of Q4 2021.

Moore Capital Management reported no remaining Moderna position as of Q4 2021 after selling out during the quarter.
Moore Capital Management sold 190,000 Moderna shares in Q4 2021, an estimated $73.1M.
Moore Capital Management first reported a position in Moderna in Q3 2021 and held it in 1 quarter.
Moore Capital Management's Moderna position peaked at $73.1M in Q3 2021.
1,109 funds tracked by Wall St. Rank held Moderna as of Q4 2021.

Based on Moore Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.